What are the contraindications for selumetinib that you need to know in advance?

Selumetinib is an oral, selective MEK1/2 inhibitor that is mainly used to treat plexiform neurofibromas associated with NF1 mutations (Neurofibromatosis Type 1, NF1). It has also shown potential in clinical studies of a variety of solid tumors. As a targeted drug, selumetinib inhibits the growth and spread of tumor cells by interfering with the MAPK/ERK signaling pathway. Although its efficacy has been confirmed in certain groups, its contraindications and risk factors still need to be fully understood before use to ensure safe use and enhance treatment benefits.

1. It is prohibited for those allergic to selumetinib ingredients

The primary contraindication to selumetinib is patients with an allergic reaction to the active ingredient or any of its excipients. Although severe allergic reactions are relatively rare in clinical practice, once they occur, such as rash, facial swelling, difficulty breathing, throat tightness and other symptoms, the drug should be stopped immediately and emergency treatment should be provided. Before taking medication, doctors should ask patients in detail whether they have any history of drug allergies, especially reactions to MEK inhibitor drugs.

2. Pregnant women should not use

Selumetinib has potential embryotoxicity and teratogenicity and is therefore expressly contraindicated in pregnant women. In animal experiments, the drug has been proven to cause fetal development abnormalities, including cardiovascular malformations, skeletal abnormalities, etc. Female patients should take effective contraceptive measures to avoid pregnancy during medication and within 1 weeks after stopping medication. For female patients of childbearing age, a pregnancy test should be performed before starting treatment to ensure that they are not pregnant before taking medicine. If you become pregnant unexpectedly during treatment, your doctor should be informed immediately and the risks of continuing treatment should be assessed.

In addition, it is not known whether selumetinib is excreted in breast milk, so breastfeeding women should also avoid using this drug to prevent potential harm to the baby. Breastfeeding should be discontinued during treatment.

3. Patients with specific underlying diseases should use it with caution or should not use it.

1. Use with caution or even prohibition in patients with severe liver dysfunction.

Selumetinib is mainly metabolized by the liver in the body. In patients with severe hepatic insufficiency, drug metabolism and clearance are slowed down, which may lead to an increase in blood drug concentration and aggravate toxic reactions. There are currently insufficient research data to clarify its safety in patients with severe liver disease, so this drug should be used with caution or contraindicated in these patients. If use is necessary, the dose should be adjusted with close monitoring of liver function.

2. Patients with heart disease are prohibited or strictly monitored

Selumetinib may cause cardiotoxicity, including decreased left ventricular ejection fraction (LVEF) or prolongation of the QT interval. Therefore, patients with a known history of severe heart failure, arrhythmia, prolongation of the QT interval, etc. need to be particularly cautious when using this drug, and it is generally recommended to be disabled. It is recommended to perform an electrocardiogram (ECG) before taking the medication (ECG) and cardiac function tests should be reviewed regularly during medication to ensure safety.

3. Patients with a history of eye diseases should use with caution

Clinical studies have found that selumetinib can cause ocular side effects, such as retinal vein occlusion, retinal epithelial detachment, and blurred vision. Patients with previous serious eye diseases such as retinopathy, glaucoma, etc. should undergo an ophthalmological evaluation before use and pay close attention to changes in vision during medication. Once significant vision loss, dark shadows, etc. occur, the medication should be discontinued immediately and seek medical attention.

4.Use with caution in patients with severe gastrointestinal diseases

Common side effects of selumetinib include diarrhea, nausea, vomiting, etc. If the patient suffers from active gastrointestinal ulcers, inflammatory bowel disease, etc., using this drug may aggravate the symptoms. Therefore, it is necessary to carefully consider whether to use it, or to take necessary preventive measures, such as giving drugs to protect the gastric mucosa.

4. Taboos caused by drug interactions

Selumetinib is a substrate metabolized by CYP3A4, so when combined with other strong CYP3A4 inhibitors or inducers, special attention must be paid to drug interactions. For example:

1.It is prohibited to combine with strong CYP3A4 inhibitors (such as ketoconazole, clarithromycin, itraconazole, etc.), because this may lead to an increase in the plasma concentration of selumetinib and increase the risk of toxicity;

2.It is prohibited to combine with strong CYP3A4 inducers (such as rifampicin, carbamazepine, phenobarbital, etc.), which may lead to weakening of the drug effect;

Concomitant use of other drugs with the risk of QT prolongation also requires caution to avoid superposition and causing serious heart rhythm problems.

3. Before using selumetinib, doctors should fully understand the patient's medication history, evaluate whether there are potential drug interactions, and change or adjust the medication regimen if necessary.

5. Children or the elderly should be cautious when using medicines

The current approved indications of selumetinib are mainly for children (≥2 years old)NF1associated plexiform neurofibromas, but age considerations still need to be taken into consideration. Children's height, weight, development indicators and adverse drug reactions should be closely monitored during medication. For elderly patients, factors such as decreased liver and kidney function and slowed drug metabolism may affect drug efficacy and tolerance. It is recommended to carefully evaluate the starting dose and strengthen follow-up.

6. Other taboos and warnings that need attention

Patients who have recently undergone major surgical procedures: Because selumetinib may interfere with wound healing, it is not recommended to be used immediately before and after surgery. In particular, selumetinib should be waited until the wound is completely healed after surgery before evaluating whether to continue taking the drug.

Patients with combined infections or immunosuppression: selumetinib may aggravate infection, especially in patients with viral, bacterial or fungal infections. The use of this drug should be considered after the infection is controlled.

Selumetinib, as a highly targeted MEK inhibitor, has shown good efficacy in specific patient groups, but it is also accompanied by certain risks and contraindications. Proper evaluation of the patient's medical history, underlying diseases and other medication conditions is the prerequisite for safe use of this drug. Special attention should be paid to pregnant women, patients with heart disease, abnormal liver function, severe eye diseases, and potential drug interaction risks to avoid serious consequences of inappropriate use. For doctors, following guideline recommendations, regularly monitoring indicators, early detection of side effects, and timely adjustment of medication regimens are the keys to ensuring long-term medication safety and efficacy for patients.

Reference materials:https://www.drugs.com/